Last reviewed · How we verify
AMG0001
At a glance
| Generic name | AMG0001 |
|---|---|
| Also known as | HGF plasmid, Collategene, beperminogene perplasmid |
| Sponsor | AnGes USA, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers (PHASE2)
- Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers (PHASE2)
- A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia (PHASE2)
- A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia
- Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia (PHASE3)
- Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG0001 CI brief — competitive landscape report
- AMG0001 updates RSS · CI watch RSS
- AnGes USA, Inc. portfolio CI